To the NCCN guidelines, PD-L1 IHC testing can be used to identify lung cancers most likely to respond to first-line anti-PD-1/PD-L1 inhibitors, while this evaluation seems unnecessary in PA; they did not report clear indications of the PD-L1 antibody clone to use for evaluating PA samples [21]. This evidence concerns the gene CD274 and lung cancer.